A Study of an Investigational Study Drug for Benign Prostatic Hyperplasia (0906-140)

Organon

Status and phase: Completed; Phase 3

Conditions: Benign Prostatic Hyperplasia

Treatments: Drug: Comparator: placebo / Duration of Treatment: 48 weeks; Drug: MK0906, finasteride / Duration of Treatment: 48 weeks

Study type: Interventional

Funder types: Industry

Identifiers

NCT00127179

0906-140

MK0906-140

2005_042

Details and patient eligibility

About

The purpose of this trial is to determine the efficacy and safety of an investigational drug in patients with benign prostatic hyperplasia.

Enrollment: 600 patients

Sex: Male

Ages: 50 to 79 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with benign prostatic hyperplasia

Exclusion criteria

• Patients who are suspected to be suffering from prostatic cancer

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind